Reported 9 months ago
Pharmaterials (6446) saw its stock price rise to a 18-month high at 567 yuan and close at 560 yuan with a 2.94% increase on June 28, benefiting from the advanced progress and better-than-expected enrollment in two clinical trials of the new drug Ropeg in the United States and Canada. The company's revenue has seen a significant increase due to the successful sales of the rare blood cancer drug Ropeg in the US market, with an 89.3% year-on-year growth in revenue in the first five months of the year. Pharmaterials continues to achieve positive results in drug certifications, recently obtaining certifications in Singapore and Malaysia, while also benefiting from a new policy in Japan that allows patients to self-inject Ropeg with a 90-day supply at once, contributing to future growth prospects.
Source: YAHOO